ABVC BioPharma Stock (NASDAQ:ABVC)
Previous Close
$0.52
52W Range
$0.41 - $2.45
50D Avg
$0.55
200D Avg
$0.81
Market Cap
$6.65M
Avg Vol (3M)
$251.00K
Beta
0.82
Div Yield
-
ABVC Company Profile
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
ABVC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KTTA | Pasithea Therapeutics Corp. |
| LGVN | Longeveron Inc. |
| ADTX | Aditxt, Inc. |
| NTRB | Nutriband Inc. |
| MNPR | Monopar Therapeutics Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| VRAX | Virax Biolabs Group Limited |
| ELDN | Eledon Pharmaceuticals, Inc. |
| RNXT | RenovoRx, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| FBRX | Forte Biosciences, Inc. |
| AKTX | Akari Therapeutics, Plc |